This analysis examines the historical and forecast performance for Lundbeck in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Lundbeck's performance against key rivals in the ethical pharmaceutical sector See how, driven by Cipralex and Lexapro royalties, Lundbeck will outperform its peer set in the period to 2012 Assess the company's late-stage pipeline prospects following the setbacks suffered by bifeprunox and desmoteplase and the abandonment of gaboxadol.